United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $258.09, for a total transaction of $929,124.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $33,551.70. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
United Therapeutics Stock Up 1.7 %
Shares of NASDAQ UTHR opened at $262.40 on Monday. United Therapeutics Co. has a 52-week low of $204.44 and a 52-week high of $262.51. The firm has a fifty day moving average of $236.86 and a 200-day moving average of $229.35. The stock has a market capitalization of $11.64 billion, a PE ratio of 12.41 and a beta of 0.54. The company has a quick ratio of 4.28, a current ratio of 3.77 and a debt-to-equity ratio of 0.04.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. During the same period in the previous year, the company earned $4.86 EPS. The business’s quarterly revenue was up 33.7% compared to the same quarter last year. On average, analysts anticipate that United Therapeutics Co. will post 23.88 EPS for the current year.
Institutional Trading of United Therapeutics
Analyst Ratings Changes
UTHR has been the subject of a number of research reports. SVB Leerink initiated coverage on shares of United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 price target for the company. Oppenheimer lifted their price objective on United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research report on Thursday. The Goldman Sachs Group lifted their price objective on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research report on Friday. Wells Fargo & Company lifted their price objective on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research report on Thursday, March 7th. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $308.78.
Read Our Latest Stock Report on UTHR
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
- Five stocks we like better than United Therapeutics
- How to Find Undervalued Stocks
- MarketBeat Week in Review – 4/29 – 5/3
- Upcoming IPO Stock Lockup Period, Explained
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- The 3 Best Blue-Chip Stocks to Buy Now
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.